usdept depart health human servic usdept usbureau food drug administr usbureau rindock docket 93n0317 rindock doctitl albuquerqu substanc abus clinic denial hear revoc approv narcot addict treatment program final order doctitl agenc agenc food drug administr hh agenc action action notic action summari summari food drug administr fda revok approv applic approv use methadon treatment program form fda2632 held albuquerqu substanc abus clinic inc asac sponsor fail demonstr abil correct prevent violat fda methadon regul also fda deni asac request hear fail submit inform show genuin issu fact justifi hear summari date effect date februari 4 1994 date inform contact gerald r hajarian center drug evalu research hfd342 food drug administr 7500 standish pl rockvil md 20855 3015941029 supplem supplementari inform feder regist septemb 23 1993 58 fr 49519 fda publish notic opportun hear nooh propos revok approv asac form fda2632 recur egregi violat fda methadon regul 291 505 21 cfr 291 505 septemb 23 1993 nooh 1 set forth detail specif violat found three fda inspect conduct april 2 1991 septemb 11 1992 2 describ fda two unsuccess effort arrang inform confer allow asac opportun explain program approv revok 3 offer asac opportun hear propos revok approv letter date octob 19 1993 asac submit written notic appear request hear fail submit inform analys demonstr genuin issu fact justifi hear fda associ commission regulatori affair review asac notic appear request hear well data file docket manag branch hfa305 food drug administr rm 123 12420 parklawn dr rockvil md 20857 submit center drug evalu research support nooh conclud asac fail rais genuin substanti issu fact requir hear 314 200 21 cfr 314 200 summari judgment enter asac reason decis set forth section ii document legisl regulatori background control substanc act pub l 91513 21 u c 801 et seq methadon classifi schedul ii control substanc 21 u c 812 c schedul ii classif mean methadon regard current accept medic use high potenti abus may lead sever psycholog physic depend 21 u c 812 b methadon synthet narcot analges approv fda 1 relief sever pain 2 detoxif treatment narcot addict 3 temporari mainten treatment narcot addict discuss section use methadon mainten treatment narcot addict permit use approv methadon program e program found accord condit distribut use methadon set forth 291 505 reason restrict methadon potenti abus divers legitim commerc illeg marketplac current action revok approv methadon program form fda2632 first action fda taken 20 year regul methadon program follow discuss intend provid legisl regulatori histori underli action seriou natur asac violat fda respons clearli understood current system fda regul monitor use methadon treatment addict began 1970 passag comprehens drug abus prevent control act 1970 cdapca pub l 91513 21 u c 801 et seq prior cdapca fda control methadon base exclus fda regul new drug includ investig use new drug section 505 feder food drug cosmet act act 21 u c 355 cdapca direct secretari health human servic determin appropri method profession practic medic treatment narcot addict variou class narcot addict 42 u c 257a secretari author determin safeti effect drug approv new drug use treatment narcot addict deleg commission food drug 5 10 8 21 cfr 5 10 8 practition wish prescrib dispens control drug includ methadon requir cdapca regist annual drug enforc administr dea feder regist april 2 1971 36 fr 6075 fda publish guidelin investig use methadon mainten treatment purpos guidelin assur avail valid data use methadon mainten treatment protect commun hazard divers abus methadon fda posit restrict use methadon mainten treatment investig new drug applic ind protocol warrant methadon avail addict consent use approv treatment program hand fda awar despit distribut restrict ind protocol effect use methadon outsid ind protocol substanti fda concern usual form new drug applic nda approv would lead even greater divers misus drug would permit rel unrestrict distribut allow physician wide discret prescrib drug therefor fda exercis author ind nda control mechan well author grant cdapca ensur requir inform assess safeti efficaci methadon would obtain close control would maintain distribut administr dispens drug 1972 fda issu methadon regul new drug provis section 505 act cdapca regul set forth medic standard treatment narcot addict accord cdapca provid close system methadon distribut earli 1970 divers methadon legitim commerc illeg marketplac becam seriou problem author dea impos enforc standard relat secur divers narcot drug use treatment narcot addict strengthen 1974 congress enact narcot addict treatment act 1974 nata pub l 93281 21 u c note nata ensur bona fide narcot addict admit mainten detoxif treatment receiv qualiti care illicit divers limit nata practition dispens narcot drug treatment narcot depend person must obtain annual registr dea registr distinct gener registr requir previous mention cdapca prescrib dispens control drug regist practition must compli requir establish dea secur drug storag recordkeep unsupervis use practition must found qualifi treatment standard establish fda methadon regul engag treatment 21 u c 823 g feder regist septemb 19 1980 45 fr 62694 fda nation institut drug abus jointli issu final rule amend fda methadon regul make consist requir nata implement regul issu dea chang includ requir physiolog depend patient physician staf urin test methadon mainten program flexibl clinic standard clarif patient care respons indic minimum standard appropri method profession practic medic treatment narcot addict recommend regard sound medic practic safe effect treatment narcot addict methadon ii asac hear request fda find asac 117 quinci st ne albuquerqu nm 87124 substanc abus treatment clinic one primari function dispens methadon hydrochlorid treatment narcot addict heroin morphin like drug nooh propos revok approv asac form fda2632 set forth detail long list seriou violat fda methadon regul violat continu recur extend period time asac shown inabl function accord methadon regul fact asac unabl bring complianc methadon regul multipl inspect clear evid manag asac suit run narcot treatment center use methadon moreov sinc public nooh fda becom awar asac longer medic director narcot treatment center use methadon treatment cannot legal function without medic director see inter alia 291 505 c 4 ii asac entir hear request consist follow statement date octob 19 1993 letter sent request hear asac may show approv narcot treatment program revok gather togeth inform data show caus us remain open hope data demonstr abil correct prevent violat inform follow within next thirti day sincer hope accept allow request hear asac submit addit inform request noth notic appear state nooh hear request must set forth specif fact show genuin issu fact requir hear asac fail even attempt submit inform therefor reason state septemb 23 1993 nooh reason discuss final order associ commission regulatori affair herebi enter summari judgment asac revok approv asac applic approv use methadon treatment program form fda2632 effect februari 4 1994 dea new mexico state author notifi concurr issuanc notic associ commission determin asac qualifi engag treatment respect registr section 303 control substanc act 21 u c 823 previous grant notic issu author deleg commission food drug 5 10 9 redeleg associ commission regulatori affair 21 cfr 5 20 date januari 24 1994 supplem signer ronald g chesemor signer signjob associ commission regulatori affair signjob frfile fr doc 942470 file 2394 8 45 frfile bill bill code 416001f bill